CMC Biologics Announces Appointment Of New CEO

COPENHAGEN, Denmark and SEATTLE and BERKELEY, Calif., Oct. 20, 2015 /PRNewswire/ -- CMC Biologics, Inc., a global leader in commercial manufacturing of therapeutic proteins with operations in Copenhagen, Denmark, Seattle, Washington and Berkeley, CA USA, announced today the promotion of Gustavo Mahler, to be effective January 1st 2016, to serve as its Chief Executive Officer. CMC Biologics, a company with 500 employees globally, is committed to delivering  world-class, fully integrated, biopharmaceutical process development and manufacturing services for clinical and commercially launched biological medicines.

Gustavo Mahler, PhD, CMC Biologics' Incoming CEO
Gustavo has more that 20 years of executive management experience in biologics manufacturing and development.  Gustavo joined the company as head of the Seattle facility in 2008. He was promoted to President of US operations and then became the COO for the Company's global operations.

"This transition of Gustavo taking over the CEO responsibility from Claes Glassell has been planned for a long time.  We are excited that Gustavo can continue the leadership of the Company through a seamless  transition. Claes has been with CMC Biologics for more than 10 years, first as a board director and as CEO since 2011. He will continue as a board director and we are grateful for his commitment and the industrial experience he brought to the company.  Claes will continue to assist CMC Biologics in its growth and continued success," said David Kauffmann, Chairman of the Board of CMC Biologics, and Managing Partner of European Equity Partners.

"Leading the CMC Biologics Executive Team is a great priviledge at this moment in our history where the company maintains world leadership as a biologics CDMO offering services for both products in development and in market. The Company is experiencing strong growth which is a testament to the  Company's world-class service offering, management and science team," said Gustavo.

Prior to joining CMC Biologics, Gustavo was head of manufacturing at the Bayer Healthcare biotechnology plant in Berkeley, California.  Gustavo worked for 15 years at Bayer in the United States, Europe and Latin America serving in various manufacturing and management positions.   He received his PhD in biochemistry from the University of Buenos Aires, and has a Master of Business Administration degree from the University UNED of Madrid and an Executive Certification in Management from MIT Sloan.

"I have truly enjoyed my role as CEO at CMC Biologics in a period of growth and expansion for the company. Having known and worked with Gustavo for a number of years, I am delighted that he has accepted the position as CEO," said Claes Glassell.  "I see this as a natural development for both the Company and Gustavo. As a board director,  I look forward to continue to working with Gustavo and contributing my experience and industry knowledge to the board's strategic discussions."

About CMC Biologics
CMC Biologics is leading the industry among CMOs in reliability, technical excellence, and quality Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical, and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation development, and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at

CMC Biologics.
Photo -
Logo -


To view the original version on PR Newswire, visit:

SOURCE CMC Biologics, Inc.